Clinically, the presence of CD4+ T cells in the peripheral blood of lung cancer patients before immune checkpoint blockade therapy is associated with increased tumor-infiltrating CD8+ T cells and better response to PD-1 therapy [37,38]. The gene discussed is CD4; the disease is lung cancer.